EmrE is a Small Multidrug Resistance transporter (SMR) family member that mediates counter transport of protons and hydrophobic cationic drugs such as tetraphenylphosphonium (TPP + ), ethidium, propidium and dequalinium. It is thought that the selectivity of the drug binding site in EmrE is defined by two negatively charged glutamate residues within a hydrophobic pocket formed from six of the α-helices, three from each monomer of the asymmetric EmrE homodimer. It is not apparent how such a binding pocket accommodates drugs of various sizes and shapes or whether the conformational changes that occur upon drug binding are identical for drugs of diverse chemical nature. Here, using electron cryomicroscopy of EmrE two-dimensional crystals we have determined projection structures of EmrE bound to three structurally different planar drugs, ethidium, propidium and dequalinium. Using image analysis and rigorous comparisons between these density maps and the density maps of the ligand-free and TPP + -bound forms of EmrE, we identify regions within the transporter that adapt differentially depending on the type of ligand bound. We show that all three planar drugs bind at the same pocket within the protein as TPP + . Furthermore, our analysis indicates that, while retaining the overall fold of the protein, binding of the planar drugs is accompanied by small rearrangements of the transmembrane domains that are different to those that occur when TPP + binds. The regions in the EmrE dimer that are remodelled surround the drug binding site and include transmembrane domains from both monomers.
Introduction
EmrE is an Escherichia coli Small Multidrug Resistance (SMR) protein that couples inward translocation of two protons with the countertransport of a broad range of hydrophobic cations, such as tetraphenylphosphonium (TPP + ), ethidium and methyl viologen. 1, 2 EmrE contains 110 amino acids that form four transmembrane (TM) α-helices. 3, 4 A low resolution (7.5 Å) projection structure 3 and 3D structure of EmrE in complex with its substrate TPP + have been determined by electron cryomicroscopy (cryo-EM) of two-dimensional (2-D) crystals. 5 The structure revealed that EmrE is composed of eight helices arranged as an asymmetric dimer within the membrane. The dimeric arrangement of EmrE was corroborated by analytical ultracentrifugation and substrate binding studies. 6, 7 EmrE has been proposed to adopt a dual topology configuration in the bacterial membrane, based on the low-resolution structural information, 5 GFP/PhoA fusion-based topology mapping and mutagenesis, 8 although this has been disputed based mainly on cross linking data. 9 The lowresolution cryo-EM structure revealed the position of TPP + in the middle of an eight-helix transmembrane bundle. 5 Based upon cryo-EM data and evolutionary constraints, a model for EmrE has been built; 10 the model is supported by extensive mutagenesis studies that identified residues likely to be involved in substrate binding. 1, 11, 12 *Corresponding author. E-mail address: cgt@mrc-lmb.cam.ac.uk.
To achieve multi-specific drug binding and transport EmrE has evolved a hydrophobic pocket with a pair of negatively charged glutamic acid residues (Glu14), which are crucial for direct transporterligand interactions, substrate translocation and coupling to the transmembrane proton gradient. 13 By analogy with the soluble multidrug binding proteins QacR 14 and BmrR, 15 the binding site of EmrE could be assumed not to require a perfect stereochemical fit with the drugs, which is believed to be a common principle in all multidrug binding proteins. 13 Binding of hydrophobic cations to EmrE is therefore thought to be via non-specific hydrophobic interactions and the ionic forces between the two E14 residues and the delocalized positive charge of the drug. Such a 'simple' binding pocket would reduce the evolutionary constraints on the protein and ensure broad substrate specificity. However, it is not clear how the binding of EmrE can accommodate drugs of different sizes and Fig. 2 . The projection maps of planar drug-bound EmrE. (a-c) The 2-D crystals of EmrE bound to an indicated drug were subjected to cryo-EM and image analysis, as described under "Materials and Methods" (Eth + ,ethidium; PP 2+ , propidium; DQ 2+ , dequalinium). The projection maps were plotted using NPO, with contours ranging from −500 to 500, with a step of 25; the 0 contour is omitted. The crystallographic asymmetric unit consists of a tetramer composed of two asymmetric dimers related by an in-plane 2-fold axis. One tetramer is coloured red and the other blue.
Results

Crystallization of EmrE with various substrates
EmrE was previously crystallized by dialysis in the presence of lipids to form 2-D crystals either with or without bound TPP + , a high-affinity substrate 3, 5, 16 that binds to EmrE with an affinity of 2 nM 7 . All the previously obtained projection maps and the lowresolution 3D structure of EmrE were determined using these 2-D crystals. To gain insights into the mechanisms underlying the substrate promiscuity of EmrE, it was critical to gather structural data on its complexes with other drugs. Therefore, three different substrates were chosen to investigate properties of the EmrE drug binding pocket. Ethidium (Eth + ), propidium (PP 2+ ) and dequalinium (DQ 2+ ) all differ structurally from TPP + by being predominantly planar molecules rather than tetrahedral (Fig. 1a) . 23 (Fig. 1c) , suggesting that the structural data would be dominated (N 97%) by contributions from EmrE bound to the exchanged ligand. Under the conditions used for the ligand exchange, equilibrium was nearly reached, but longer incubations could have resulted in a further deterioration of crystallinity, so exchange reactions were limited to 5 h.
Projection structures of ethidium-, propidium-and dequalinium-bound EmrE
The crystals obtained in the presence of Eth + were smaller than the TPP + -bound crystal form, but reasonably well ordered, judged by optical diffraction of the cryo-EM micrographs and further image processing. The projection structure was obtained by merging data from the 12 best images. The resolution of the projection structure extended to 7 Å, comparable to that of the previously determined EmrE projections with and without TPP + (Fig. 2a , Table 1 ). The crystals that underwent ligand exchange (PP 2+ -and DQ 2+ -bound crystal forms) were morphologically indistinguishable from the parental TPP + -bound EmrE 2-D crystals. However, image processing 
Averaged projection structures of EmrE bound to mono-and bivalent planar substrates
At the resolution of the projection maps obtained, all secondary structure features seen in the higher resolution projections of EmrE were clearly resolved (Fig. 2) . The repetitive unit in the crystals was the crystallographic tetramer (coloured either blue or red in each of the maps in Fig. 2 ), but previous work shows that the minimal functional unit for substrate binding is the dimer. 7 Careful inspection clearly revealed small differences between the two halves of the tetramer related by two fold non-crystallographic symmetry of EmrE in each of the projection maps. These discrepancies between the dimers were more pronounced in the density maps obtained with PP 2+ and DQ 2+ , where only a limited amount of data was available. To improve further the resolution of the asymmetric dimer, the two dimers in the crystallographic tetramer were averaged using the MRC software for electron micrograph analysis, 17 as described in "Materials and Methods". The resulting averaged maps calculated from the data and merged to 7 Å are shown in Fig. 3 . Evident from the red contours in Fig. 3 , the asymmetry within the crystallographic tetramer was highest in the PP 2+ -bound EmrE projection map, although the data extended to about the same resolution as that for the DQ 2+ -bound form ( Table 2 , "RMS mirr.").
The three projection structures of EmrE were superficially similar to each other and to those obtained previously (Fig. 3) . In order to quantitatively assess the similarity between all ligand-bound (TPP + and planar drugs) and ligand-free (apo-) EmrE projection maps, we also calculated the averaged dimer TPP + -EmrE map from the p2-symmetrised projection structure 16 (as described under "Materials and Methods"; Fig. 4b , Table 2 ).
The apo form (Fig. 4a) did not require averaging, because the projection maps from which it was derived were in space group c222 that contains a crystallographic in-plane 2-fold relating the two asymmetric dimers in the tetramer. 16 Thus, interpolation and averaging served two purposes, improving the signal/noise level in the resulting projection structures and, more importantly, allowing the direct and DQ 2+ ) or c222 symmetry (apo-EmrE). The resolution at which the comparisons of all maps could be performed was limited by the resolution of the DQ 2+ -bound EmrE map (effective resolution threshold of 8.2 Å). To choose an optimal resolution, we merged and averaged all five maps at 7, 8, 9 and 10 Å. We then determined the "RMS difference" (the RMS deviation of the total density from the average density in the map; Table 2 ) for difference maps between each projection map and the TPP + -EmrE. We found that the RMS deviations, and therefore the experimental error, were lowest at 9 Å for all planar ligand-bound EmrE projection maps. Therefore, all maps were compared and cross-correlated at 9 Å resolution. The maps of TPP + -EmrE, Eth + -EmrE and apo-EmrE contained structural information below that threshold, and were compared separately at 7 Å resolution.
Detailed comparisons between projection maps
Comparisons were made between all the projection maps and plotted at either 9 Å resolution (Fig. 4) or, where the data allowed, at 7 Å resolution (Fig. 5) . Table 3 provides the cross-correlation coefficients for all the comparisons. From these data it is clear that there are three distinct projection structures, namely apo-EmrE, TPP + -bound EmrE and planar drugbound EmrE. The differences between apo-EmrE and TPP + -EmrE have been previously described 16 and are reproduced in Fig. 4b , with the large negative density peak at the B2/C2 boundary representing bound TPP + . Figure 4c -e show similar negative peaks, which are likely to represent either Eth + , PP 2+ or DQ 2+ in each case. In addition, there are density differences in each of the different density maps for Eth + , PP 2+ and DQ 2+ in the C1 area, suggestive of a movement of this helix, as seen upon TPP + binding, although there appears to be an increase in the magnitude of the movement when planar drugs are bound, compared to TPP + ( Fig. 4f-h ). Additional changes are seen in the areas A3, D3 and D4 of the 7 Å resolution map 'Eth + minus TPP + ' (Fig. 5c ). These changes are associated with the helices that form the substrate binding pocket, whereas there appear to be fewer and smaller density changes associated with the pair of helices in squares B&C, 4&5. These two helices may represent helix 4, one from each monomer, and are notable in that they are about 9 Å apart centre to centre along their whole length and so probably represent a strong and stable association; in addition, being separated from the ligand binding pocket, it is unlikely they are contributing to any conformational change during ligand binding.
Discussion
Versatile recognition of diverse chemical structures is a feature of the multidrug binding proteins and transporters. Most of what we know about the structural basis of multi-specific drug recognition comes from the structural studies on the soluble 14, 15 and from the X-ray structures of the multidrug transporter of the RND family member, AcrB 20 (several other putative multidrug transporter structures have been solved, albeit without any substrates bound 18, 19 ). The structures of these proteins revealed large drug binding sites containing discrete subsites in which different drugs can bind. 14, 15, 20 In some cases, binding of several drugs was shown to occur simultaneously, leading to a 'cross-talk' between the ligands and their binding sites. 20, 21 Importantly, in all cases where multidrug binding proteins or transporters were co-crystallized with the drugs, recognition of different drugs by the same binding site was associated with little, if any, difference in the conformational state of the protein. 13 The drug binding site of EmrE is formed by the transmembrane domains of the protein. This puts several evolutionary constraints on the EmrE drug binding site: (i) there must be at least two orientations of the substrate binding site (inward-and outward-facing orientation), with different affinities for the substrates, allowing substrate translocation across the bacterial inner membrane; (ii) inherently, this implies a certain degree of flexibility of the protein; (iii) specificity for multiple drugs must be combined with strong coupling to the H + -gradient, preventing 'leaky' passage of ions or small molecules. Maintaining these three conditions would present a challenge for a small protein like EmrE with a large pocket containing multiple discrete binding sites for different classes of drugs.
Here, using cryo-EM we show that, to accommodate drugs with planar and tetrahedral geometry, EmrE undergoes distinct conformational rearrangements. The structural changes are similar for monoand bivalent planar drugs (Eth + and PP 2+ , respectively). We are able to identify the position of the bound ligand in all three new projection structures at 9 Å resolution (confirmed for Eth + -EmrE down to 7 Å resolution), confirming that there are no subsites for different substrates in the EmrE binding site. Furthermore, we identify three regions surrounding the drug binding site, which change in response to binding of planar drugs (Eth + , PP 2+ and DQ 2+ ) in a way different from the changes upon TPP + binding. Remodelled regions of the protein include transmembrane helices in area A2 and B3, as well as the junction between helices at the boundary between areas 2 and 3. The peak corresponding to movement of the helix in area C1 is broadened in the planar drug-EmrE projection structures, although its position is not greatly changed. This may indicate intrinsic flexibility of this region of the protein, a property that may be necessary for drug binding and translocation across the membrane. The precise nature of the conformational changes will remain unresolved until 3D structures at higher resolution become available.
Our findings indicate that in contrast to other multidrug binding proteins, rather than having a large cavity with discrete niches for different substrates, EmrE has evolved a binding site that is remodelled dependent on the geometry of the substrate. Remodelling is achieved by subtle changes in the structure of the protein, resulting in altered positions of the transmembrane domains within the projection structures.
Materials and Methods
Protein expression and purification
Expression and purification of EmrE was performed as described previously. 3 Briefly, E. coli membranes containing 6xHis-tagged EmrE were solubilized with dodecylmaltoside (DDM, Glycon, Germany). The protein was then purified using a 3-step procedure that included NiNTA-agarose (Qiagen), gel filtration (Superdex 200, Amersham) and anion exchange (PI, Poros). Purity of the protein preparations was assessed by SDS-PAGE.
Radioligand binding assays
To quantify the efficiency of ligand exchange at the 2-D crystals, radioligand binding assays were used. For that purpose, the 2-D crystals obtained with TPP + were subjected to dialysis against a low pH buffer (pH 5), to remove bound TPP + . A saturating amount of the resulting 2-D crystals was mixed with [ 3 H]TPP + (final concentration 400 nM; Amersham) in the crystallization buffer (Tris pH 7.5, NaCl 100 mM, ethylenediaminetetraacetic acid (EDTA) 1 mM). The mix was diluted 1000-fold with the crystallization buffer in the absence and in the presence of propidium iodide (15 μM) or dequalinium (50 μM). After 5 h incubation at 22°C, 1 ml of the diluted mix was filtered though GF/B filter (Millipore) and washed with ice-cold buffer. Liquid scintillant was added and radioactivity bound to the filter was counted. Non-specific binding was determined by adding 100 μM cold TPP + (Sigma). Competition binding assays were performed as described previously. 6 
2-D crystallization
Crystallization of tubular crystals of EmrE in complex with ethidium bromide was performed essentially as Table 3 . Cross-correlation coefficients for the comparison of all possible combinations of difference maps Abbreviations used here: A, T, E, P and D stand for apo-EmrE, TPP + , ethidium, propidium and dequalinium, respectively; thus 'A-T' indicates the difference density map calculated by subtracting the density for TPP + -bound EmrE from the density for apo-EmrE. a Cross-correlation coefficients determined using the difference maps calculated at 7 Å resolution are shown in parentheses.
that for the TPP + -bound form. 3 EmrE at concentration of 0.5-1 mg/ml was mixed with dimyristoylphosphatidylcholine (DMPC; Avanti Polar Lipids) at lipid to protein ratios of 0.3-0.4. Crystallization was performed in a dialysis cassette (Slide-a-lyzer, 10 kDa cut-off, 0.1-0.5 ml, Pierce) for a week, with a daily buffer exchange (pH 7.5) with a buffer containing 1 mM ethidium bromide.
Ligand exchange
To obtain the crystals of EmrE bound to propidium iodide and dequalinium, the TPP + -bound EmrE crystals were employed. A suspension of the TPP + -EmrE crystals (100 μl, 1 mg/ml protein concentration, 200 nM TPP + ) was dialysed for 5 h at 22°C against a 1000-fold excess of the same buffer containing the desired ligand (50 μM propidium or 15 μM dequalinium; Sigma). The concentrations of propidium and dequalinium were well above the determined K i values (2632 times and 181 times, respectively) for binding to EmrE. A 1000-fold dilution of the TPP + in the crystal suspension dilutes it to 10-fold below its K d to optimise ligand exchange. In Fig. 1c , this would mean equilibrium would have been reached if the amount of 3 H-TPP + left bound was 3.5 dpm, whereas after exchange the amount left bound when exchanged for propidium was 105 dpm and 35 dpm in the presence of unlabelled TPP + or dequalinium. Longer incubations were avoided to prevent deterioration of the crystals.
Electron microscopy
Crystals were deposited onto glow-discharged carboncoated electron microscopy grids, blotted, washed with a solution containing 2% glucose, blotted again, and plunged into liquid nitrogen. The frozen grids were loaded onto a liquid nitrogen-cooled Gatan 626 cryostage and analysed by low-dose cryo-EM techniques (10-15 e Å − 2 ) on a Technai F20 electron microscope at an accelerating voltage of 200 keV. Images were collected with flood beam illumination at a magnification of 50,000×-58,000×. The quality of the images was assessed by optical diffraction. The best images were digitized using the MRC KZA scanner with a 6 μm step size. 22 Image processing was performed using the MRC package. Projection structures were built according to previously described procedures, using MRC software. 17 Averaging of the asymmetric dimers within the crystallographic tetramer was done using INTERPO, a program for image interpolation. In brief, the p2 maps were rotated by approximately 17°(slightly different angles were used for each map; Table 2 ), to enable assignment of an orthogonal (90°) coordinate system to each projection map. This allowed the direct comparison of maps from either p2 or c222 crystal forms. An area corresponding to the EmrE crystallographic tetramer was cut out from each map using LABEL, and then the same program was used to create a mirror image of the cut out image. TWOFILE was then used to calculate difference maps between the two mirror images. Iterative adjustment of the angle of rotation and the position of the cut out region was performed until the lowest RMS deviation of the mirror difference map was reached ("RMS mirr."; Table 2 ). The procedure was repeated with all projection maps merged at 7, 8, 9 and 10 Å resolution. TWOFILE was then used to compare the averaged projection maps at corresponding resolutions; each projection map was scaled to obtain minimal RMS of the difference map ("RMS diff."; Table 2 ). Crosscorrelation of the difference maps was performed with the mean density values, using the equation: σ = (A·B)/ sqrt(A 2 ·B 2 ), where A and B are mean densities of the two correlated difference maps; multiplication of images required for the cross-correlation calculation was done using TWOFILE.
